MA26821A1 - Sel polymorphe - Google Patents

Sel polymorphe

Info

Publication number
MA26821A1
MA26821A1 MA26556A MA26556A MA26821A1 MA 26821 A1 MA26821 A1 MA 26821A1 MA 26556 A MA26556 A MA 26556A MA 26556 A MA26556 A MA 26556A MA 26821 A1 MA26821 A1 MA 26821A1
Authority
MA
Morocco
Prior art keywords
polymorphic salt
polymorphic
salt
Prior art date
Application number
MA26556A
Other languages
English (en)
Inventor
Bentley Arthur
James Ogilvie Ronald
Arnold Howard-Field Simon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26821A1 publication Critical patent/MA26821A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26556A 1999-09-28 2002-03-15 Sel polymorphe MA26821A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt

Publications (1)

Publication Number Publication Date
MA26821A1 true MA26821A1 (fr) 2004-12-20

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26556A MA26821A1 (fr) 1999-09-28 2002-03-15 Sel polymorphe

Country Status (50)

Country Link
US (1) US6369094B1 (fr)
EP (1) EP1233960B1 (fr)
JP (1) JP3795395B2 (fr)
KR (1) KR100479897B1 (fr)
CN (1) CN1155594C (fr)
AP (1) AP2004A (fr)
AR (1) AR025779A1 (fr)
AT (1) ATE246185T1 (fr)
AU (1) AU779580B2 (fr)
BG (1) BG65161B1 (fr)
BR (1) BR0014272A (fr)
CA (1) CA2379572C (fr)
CO (1) CO5180567A1 (fr)
CR (1) CR6561A (fr)
CU (1) CU23200A3 (fr)
CZ (1) CZ2002971A3 (fr)
DE (1) DE60004262T2 (fr)
DK (1) DK1233960T3 (fr)
DZ (1) DZ3254A1 (fr)
EA (1) EA004510B1 (fr)
EE (1) EE200200171A (fr)
EG (1) EG24143A (fr)
ES (1) ES2200911T3 (fr)
GB (1) GB9922963D0 (fr)
GE (1) GEP20043365B (fr)
GT (1) GT200000159A (fr)
HK (1) HK1048628B (fr)
HR (1) HRP20020270B1 (fr)
HU (1) HUP0202821A3 (fr)
IL (1) IL147154A (fr)
IS (1) IS2162B (fr)
MA (1) MA26821A1 (fr)
MX (1) MXPA02003311A (fr)
MY (1) MY121170A (fr)
NO (1) NO321936B1 (fr)
NZ (1) NZ516093A (fr)
OA (1) OA12024A (fr)
PA (1) PA8498901A1 (fr)
PE (1) PE20010662A1 (fr)
PL (1) PL354960A1 (fr)
PT (1) PT1233960E (fr)
SI (1) SI1233960T1 (fr)
SK (1) SK3982002A3 (fr)
TN (1) TNSN00187A1 (fr)
TR (1) TR200200804T2 (fr)
TW (1) TWI265926B (fr)
UA (1) UA72272C2 (fr)
WO (1) WO2001023377A2 (fr)
YU (1) YU2602A (fr)
ZA (1) ZA200202406B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
AU2005311714B2 (en) * 2004-12-03 2010-09-30 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
WO2007047447A2 (fr) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Analogues de compose diuretique ou de type diuretique
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (fr) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Nouveau polymorphe de bromhydrate d'életriptan et son procédé de fabrication
RS62600B1 (sr) 2009-10-26 2021-12-31 Merck Sharp & Dohme Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
WO1999001135A1 (fr) 1997-07-03 1999-01-14 Pfizer Limited Compositions pharmaceutiques contenant hemisulfate d'eletriptane et cafeine

Also Published As

Publication number Publication date
TWI265926B (en) 2006-11-11
BG65161B1 (bg) 2007-04-30
KR100479897B1 (ko) 2005-03-31
PT1233960E (pt) 2003-11-28
ZA200202406B (en) 2003-05-28
PL354960A1 (en) 2004-03-22
GEP20043365B (en) 2004-05-10
CA2379572C (fr) 2006-11-14
MY121170A (en) 2005-12-30
DK1233960T3 (da) 2003-10-27
NO20021525D0 (no) 2002-03-26
CN1155594C (zh) 2004-06-30
NZ516093A (en) 2005-01-28
JP2003510318A (ja) 2003-03-18
HUP0202821A2 (hu) 2003-01-28
DE60004262D1 (de) 2003-09-04
TNSN00187A1 (fr) 2005-11-10
HRP20020270B1 (en) 2004-04-30
NO321936B1 (no) 2006-07-24
ATE246185T1 (de) 2003-08-15
CZ2002971A3 (cs) 2003-04-16
IL147154A (en) 2005-11-20
NO20021525L (no) 2002-03-26
EA004510B1 (ru) 2004-04-29
PE20010662A1 (es) 2001-06-23
HRP20020270A2 (en) 2003-06-30
EE200200171A (et) 2003-06-16
WO2001023377A2 (fr) 2001-04-05
EG24143A (en) 2008-08-06
DZ3254A1 (fr) 2001-04-05
CN1364166A (zh) 2002-08-14
CO5180567A1 (es) 2002-07-30
HK1048628B (zh) 2004-10-21
WO2001023377A3 (fr) 2002-03-07
HUP0202821A3 (en) 2003-12-29
UA72272C2 (uk) 2005-02-15
BR0014272A (pt) 2002-05-21
AU779580B2 (en) 2005-01-27
OA12024A (en) 2006-04-19
GT200000159A (es) 2002-03-20
AU6721300A (en) 2001-04-30
CA2379572A1 (fr) 2001-04-05
CU23200A3 (es) 2007-04-06
WO2001023377A9 (fr) 2002-03-28
YU2602A (sh) 2004-11-25
EA200200302A1 (ru) 2002-10-31
JP3795395B2 (ja) 2006-07-12
KR20020032627A (ko) 2002-05-03
IS2162B (is) 2006-11-15
BG106240A (en) 2002-07-31
TR200200804T2 (tr) 2002-07-22
HK1048628A1 (en) 2003-04-11
CR6561A (es) 2005-04-04
ES2200911T3 (es) 2004-03-16
DE60004262T2 (de) 2004-01-22
GB9922963D0 (en) 1999-12-01
IS6223A (is) 2002-01-08
EP1233960B1 (fr) 2003-07-30
SK3982002A3 (en) 2003-05-02
MXPA02003311A (es) 2002-10-04
SI1233960T1 (en) 2003-12-31
AR025779A1 (es) 2002-12-11
PA8498901A1 (es) 2004-02-07
US6369094B1 (en) 2002-04-09
AP2004A (en) 2009-06-10
EP1233960A2 (fr) 2002-08-28
AP2002002457A0 (en) 2002-06-30
IL147154A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
EE200100502A (et) Ühendid
DK1224180T3 (da) Substituerede azoler
PT1202994E (pt) Novos compostos
EE200200224A (et) Uudsed ühendid
DE50014679D1 (de) Substituierte indol-mannichbasen
IS6139A (is) Ný efnasambönd
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
DZ3254A1 (fr) Sel polymorphe
NO20013769L (no) Kalsilytiske forbindelser
DE60045158D1 (de) Aussenbordmotor
NO20020466L (no) Kalsilytiske forbindelser
DE60024023D1 (de) Nockenwellenversteller
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
DE10081188D2 (de) Melken
HU0103064D0 (en) New polymorphic salt
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
FIU990399U0 (fi) Perhouistin vapakalastukseen
SE9901270D0 (sv) Novel compounds
SE9904651D0 (sv) Novel compounds
SE9903080D0 (sv) Novel compounds
SE9901118D0 (sv) Novel compounds
SE9901078D0 (sv) Novel compounds
SE9901271D0 (sv) Novel compounds
SE9902764D0 (sv) Novel compounds